Pembrolizumab Associated Autoimmune Diabetes Mellitus: Case Series

被引：0

作者：

Ozkan, Oguzcan ^{[1
]}

Gecgel, Ashi ^{[1
]}

Gokmen, Erhan ^{[1
]}

机构：

[1] Ege Univ, Fac Med, Dept Med Oncol, Izmir, Turkiye

来源：

NAMIK KEMAL MEDICAL JOURNAL | 2024年 / 12卷 / 03期

关键词：

Autoimmune diabetes; intensive insulin therapy; immunotherapy-related adverse events; cancer immunotherapy; pembrolizumab induced diabetes mellitus; IMMUNOTHERAPY;

D O I：

10.4274/nkmj.galenos.2024.48726

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The use of immune checkpoint inhibitors is increasing every day. With such frequent use, the side effects and management associated with these treatments are becoming difficult. One of rare side effects is autoimmune diabetes mellitus. In this review, we will discuss two cases of pembrolizumab-associated diabetes mellitus treated in our clinic and those reported in the literature. Most of the reported cases presented with diabetic ketoacidosis and they were on insulin therapy. The relationship between diabetes and immune checkpoint inhibitors needs to be clarified.

引用

收藏

页码：239 / 242

页数：4

相关论文

共 15 条

[1] Immune checkpoint inhibitor-induced Type 1 diabetes: a systematic review and meta-analysis [J].

Akturk, H. K. ;

Kahramangil, D. ;

Sarwal, A. ;

Hoffecker, L. ;

Murad, M. H. ;

Michels, A. W. .

DIABETIC MEDICINE, 2019, 36 (09) :1075-1081

[2]

Araki K, 2013, COLD SH Q B, V78, P239, DOI [10.1101/sqb.78.019869, 10.1101/sqb.2013.78.019869]

[3] Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies [J].

Byun, David J. ;

Wolchok, Jedd D. ;

Rosenberg, Lynne M. ;

Girotra, Monica .

NATURE REVIEWS ENDOCRINOLOGY, 2017, 13 (04) :195-207

[4]

Capitao Ricardo, 2018, BMJ Case Rep, V2018, DOI 10.1136/bcr-2017-220999

[5] A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes [J].

Chae, Young Kwang ;

Chiec, Lauren ;

Mohindra, Nisha ;

Gentzler, Ryan ;

Patel, Jyoti ;

Giles, Francis .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2017, 66 (01) :25-32

[6] Rituximab in the treatment of pembrolizumab-induced myasthenia gravis [J].

Crusz, S. M. ;

Radunovic, A. ;

Shepherd, S. ;

Shah, S. ;

Newey, V. ;

Phillips, M. ;

Lim, L. ;

Powles, T. ;

Szlosarek, P. W. ;

Shamash, J. ;

Rashid, S. .

EUROPEAN JOURNAL OF CANCER, 2018, 102 :49-51

[7] Role of the PD-1/PD-L1 Dyad in the Maintenance of Pancreatic Immune Tolerance for Prevention of Type 1 Diabetes [J].

Falcone, Marika ;

Fousteri, Georgia .

FRONTIERS IN ENDOCRINOLOGY, 2020, 11

[8] Anti-PD1 Pembrolizumab Can Induce Exceptional Fulminant Type 1 Diabetes [J].

Gaudy, Caroline ;

Clevy, Celine ;

Monestier, Sandrine ;

Dubois, Noemie ;

Preau, Yanis ;

Mallet, Stephanie ;

Richard, Marie-Aleth ;

Grob, Jean-Jacques ;

Valero, Rene ;

Beliard, Sophie .

DIABETES CARE, 2015, 38 (11) :E182-E183

[9] Tissue expression of PD-L1 mediates peripheral T cell tolerance [J].

Keir, ME ;

Liang, SC ;

Guleria, I ;

Latchman, YE ;

Qipo, A ;

Albacker, LA ;

Koulmanda, M ;

Freeman, GJ ;

Sayegh, MH ;

Sharpe, AH .

JOURNAL OF EXPERIMENTAL MEDICINE, 2006, 203 (04) :883-895

[10] Acute-onset type 1 diabetes mellitus caused by nivolumab in a patient with advanced pulmonary adenocarcinoma [J].

Kumagai, Ryo ;

Muramatsu, Aiko ;

Nakajima, Rikako ;

Fujii, Masanao ;

Kaino, Kenta ;

Katakura, Yukino ;

Okumura, Nobuhito ;

Ohara, Gen ;

Kagohashi, Katsunori ;

Satoh, Hiroaki ;

Yagyu, Hiroaki .

JOURNAL OF DIABETES INVESTIGATION, 2017, 8 (06) :798-799